Clinical Trials

Small Cell Lung Carcinoma

NCT01658462 2026-03-16

VAROCE

51 enrolled

Breast

Breast Neoplasms

NCT02856425 2026-01-20

PEMBIB

Phase 1 Active not recruiting

196 enrolled

Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT03513484 2025-10-21

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

44 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02863055 2025-09-19

NEMO

Other solid neoplasmThoracic

37 enrolled

Mesothelioma, Malignant

NCT02730416 2025-07-29

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

146 enrolled

Endometrial Neoplasms

NCT02299141 2025-06-24

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

20 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02496585 2025-04-16

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

34 enrolled 10 charts

Lung Neoplasms, Radiation Pneumonitis

NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

19 enrolled 21 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Phase 3 Terminated

12 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT01346540 2025-02-12

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

16 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02300298 2025-02-11

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02780700 2025-02-03

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

1 enrolled 5 charts

Colorectal Neoplasms

NCT02182245 2025-01-23

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

22 enrolled

Genital Neoplasms, Female

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02182219 2025-01-22

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

21 enrolled

Genitourinary

Prostatic Neoplasms

NCT02009579 2024-08-07

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

120 enrolled

Uterine Cervical Neoplasms

NCT02902484 2024-06-03

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

Phase 1/2 Terminated

14 enrolled 9 charts

Pancreatic Neoplasms

NCT02225405 2024-05-08

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02399215 2023-12-26

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

32 enrolled 12 charts

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT01583322 2023-09-06

CHIVA

188 enrolled

Ovarian Neoplasms

NCT03062943 2022-09-28

LAM

30 enrolled

Lymphangioleiomyomatosis

NCT03287947 2022-08-09

LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

5 enrolled 12 charts

Appendiceal Neoplasms

NCT02665143 2022-04-08

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Other hematologic neoplasm

25 enrolled 7 charts

Leukemia, Myeloid, Acute

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

180 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Phase 1 Terminated

11 enrolled

Ovarian Neoplasms

NCT02568449 2021-12-09

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Other solid neoplasmThoracic

20 enrolled 11 charts

Mesothelioma, Malignant

NCT02808247 2021-09-20

ANITA

80 enrolled

Sarcoma

NCT02531737 2021-08-10

REFRACT

59 enrolled

Lung Neoplasms

NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

99 enrolled 45 charts

Genitourinary

Carcinoma, Renal Cell

NCT02393755 2021-07-08

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Colonic Neoplasms, Rectal Neoplasms

NCT02668393 2021-01-29

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

14 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02234596 2021-01-25

Nintedanib in Patients With Advanced Esophagogastric Cancer

34 enrolled 9 charts

Esophagogastric Adenocarcinoma

NCT03361319 2020-11-24

N3

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02308553 2020-10-14

NIPAWILMA

Phase 1/2 Completed

33 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT01788982 2020-07-31

Nintedanib(BIBF1120) in Thyroid Cancer

100 enrolled

Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

NCT02452463 2020-04-06

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

8 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT01362361 2019-09-19

AIO-KRK-0111

54 enrolled

Colorectal Neoplasms

NCT02619162 2019-07-23

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

25 enrolled

Breast

Breast Neoplasms

NCT02389764 2019-07-17

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

10 enrolled 9 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01610869 2019-05-29

METRO-BIBF

117 enrolled

Other solid neoplasmThoracic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Recurrence

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2/3 Terminated

545 enrolled 15 charts

Mesothelioma

NCT02751385 2019-03-14

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Phase 1 Terminated

2 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00805194 2018-12-05

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Phase 3 Completed

1,314 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT01669798 2018-10-16

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

32 enrolled 19 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

30 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

21 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

NCT00801294 2017-12-29

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

46 enrolled

Colorectal Neoplasms

NCT02182063 2017-12-28

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer